New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:32 EDTORMPOramed granted 3rd patient in Australia for oral administration of exenatide
Oramed announced that IP Australia, the Australian government's patent office, has issued the company its third patent in the country. The patent, titled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology, including its ORMD-0901 oral exenatide capsule.Oramed has planned a comprehensive clinical program for ORMD-0901, with the goal of seeking approval in the U.S. and other territories. IND-enabling toxicity studies are scheduled to begin later this year in the U.S. and a Phase 1b study outside of the U.S. is also planned for 2014.
News For ORMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
09:23 EDTORMPOramed reports first screening of patient in Phase IIb trial of ORMD-0801
Subscribe for More Information
08:18 EDTORMPOramed submits protocol for Phase IIb trial of ORMD-0801 to FDA
Subscribe for More Information
June 16, 2015
08:15 EDTORMPOramed announces oral administration of GLP-1 granted patent in Russia
Oramed announced that the Russian Federal Service for Intellectual Property has granted the company a patent for its invention, titled "Methods and Compositions for Oral Administrations of Exenatide."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use